Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal

Positive

AI Analysis

Summary

Mentari Therapeutics has secured a second $200M private placement as it progresses toward closing a reverse merger with InMed Pharmaceuticals. Royalty announced a separate ATTR-CM deal.

Outcome Details

Second private placement of $200M

Importance:6/10

Sentiment:

0.50

private_placementreverse_mergermigraineATTR-CMfinancing

Related Companies

$RPRX

Read the original article

Published by Endpoints News on July 22, 2026 2:17 PM

Read Original